Vogenx, Inc. (VOGX)
| Market Cap | 196.10M |
| Revenue (ttm) | n/a |
| Net Income | -1.56M |
| EPS | -0.29 |
| Shares Out | 13.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,017 |
| Open | 13.09 |
| Previous Close | 13.00 |
| Day's Range | 13.00 - 14.20 |
| 52-Week Range | 12.95 - 14.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Financial Performance
Financial StatementsNews
Vogenx Announces Closing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for t...
Vogenx Announces Pricing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for t...
Vogenx IPO Registration Document (S-1)
Vogenx has filed to go public with an IPO on the NASDAQ
Metabolic disorders biotech Vogenx files for a US IPO
Vogenx, a Phase 2b biotech developing therapies for metabolic disorders, filed on Wednesday with the SEC to raise up to what we estimate could be $25 million in an initial public offering.